These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 25796091)

  • 41. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents.
    Jimeno A; Rubio-Viqueira B; Amador ML; Oppenheimer D; Bouraoud N; Kulesza P; Sebastiani V; Maitra A; Hidalgo M
    Cancer Res; 2005 Apr; 65(8):3003-10. PubMed ID: 15833824
    [TBL] [Abstract][Full Text] [Related]  

  • 42. p38 MAPK-induced MDM2 degradation confers paclitaxel resistance through p53-mediated regulation of EGFR in human lung cancer cells.
    Park SH; Seong MA; Lee HY
    Oncotarget; 2016 Feb; 7(7):8184-99. PubMed ID: 26799187
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cetuximab in combination with icotinib overcomes the acquired resistance caused by EGFR T790M mutation in non-small cell lung cancer].
    Wang M; Zhang L; Zhao X; Liu J; Chen Y; Wang C
    Zhonghua Zhong Liu Za Zhi; 2014 Sep; 36(9):651-6. PubMed ID: 25564053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Enhanced anticancer effects of Scutellaria barbata D. Don in combination with traditional Chinese medicine components on non-small cell lung cancer cells.
    Wang Q; Acharya N; Liu Z; Zhou X; Cromie M; Zhu J; Gao W
    J Ethnopharmacol; 2018 May; 217():140-151. PubMed ID: 29458146
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Exogenous Restoration of TUSC2 Expression Induces Responsiveness to Erlotinib in Wildtype Epidermal Growth Factor Receptor (EGFR) Lung Cancer Cells through Context Specific Pathways Resulting in Enhanced Therapeutic Efficacy.
    Dai B; Yan S; Lara-Guerra H; Kawashima H; Sakai R; Jayachandran G; Majidi M; Mehran R; Wang J; Bekele BN; Baladandayuthapani V; Yoo SY; Wang Y; Ying J; Meng F; Ji L; Roth JA
    PLoS One; 2015; 10(6):e0123967. PubMed ID: 26053020
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Polyphyllin VII increases sensitivity to gefitinib by modulating the elevation of P21 in acquired gefitinib resistant non-small cell lung cancer.
    Wang H; Fei Z; Jiang H
    J Pharmacol Sci; 2017 Jul; 134(3):190-196. PubMed ID: 28757172
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.
    Gallagher-Colombo SM; Miller J; Cengel KA; Putt ME; Vinogradov SA; Busch TM
    Cancer Res; 2015 Aug; 75(15):3118-26. PubMed ID: 26054596
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Oxymatrine inhibits non-small cell lung cancer via suppression of EGFR signaling pathway.
    Li W; Yu X; Tan S; Liu W; Zhou L; Liu H
    Cancer Med; 2018 Jan; 7(1):208-218. PubMed ID: 29239135
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Afatinib increases sensitivity to radiation in non-small cell lung cancer cells with acquired EGFR T790M mutation.
    Zhang S; Zheng X; Huang H; Wu K; Wang B; Chen X; Ma S
    Oncotarget; 2015 Mar; 6(8):5832-45. PubMed ID: 25714021
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of siRNAs targeting the EGFR T790M mutation in a non-small cell lung cancer cell line resistant to EGFR tyrosine kinase inhibitors and combination with various agents.
    Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
    Biochem Biophys Res Commun; 2013 Feb; 431(3):623-9. PubMed ID: 23266614
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models.
    Cha MY; Lee KO; Kim M; Song JY; Lee KH; Park J; Chae YJ; Kim YH; Suh KH; Lee GS; Park SB; Kim MS
    Int J Cancer; 2012 May; 130(10):2445-54. PubMed ID: 21732342
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Caffeic acid phenethyl ester induced cell cycle arrest and growth inhibition in androgen-independent prostate cancer cells via regulation of Skp2, p53, p21Cip1 and p27Kip1.
    Lin HP; Lin CY; Huo C; Hsiao PH; Su LC; Jiang SS; Chan TM; Chang CH; Chen LT; Kung HJ; Wang HD; Chuu CP
    Oncotarget; 2015 Mar; 6(9):6684-707. PubMed ID: 25788262
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo.
    Du S; Bouquet S; Lo CH; Pellicciotta I; Bolourchi S; Parry R; Barcellos-Hoff MH
    Int J Radiat Oncol Biol Phys; 2015 Jan; 91(1):91-9. PubMed ID: 25835621
    [TBL] [Abstract][Full Text] [Related]  

  • 55. AZD5438, an inhibitor of Cdk1, 2, and 9, enhances the radiosensitivity of non-small cell lung carcinoma cells.
    Raghavan P; Tumati V; Yu L; Chan N; Tomimatsu N; Burma S; Bristow RG; Saha D
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(4):e507-14. PubMed ID: 22795803
    [TBL] [Abstract][Full Text] [Related]  

  • 56. P53 and p38 MAPK pathways are involved in MONCPT-induced cell cycle G2/M arrest in human non-small cell lung cancer A549.
    Zhang C; Zhu H; Yang X; Lou J; Zhu D; Lu W; He Q; Yang B
    J Cancer Res Clin Oncol; 2010 Mar; 136(3):437-45. PubMed ID: 19727814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Targeting epidermal growth factor receptor-associated signaling pathways in non-small cell lung cancer cells: implication in radiation response.
    Choi EJ; Ryu YK; Kim SY; Wu HG; Kim JS; Kim IH; Kim IA
    Mol Cancer Res; 2010 Jul; 8(7):1027-36. PubMed ID: 20587532
    [TBL] [Abstract][Full Text] [Related]  

  • 58. G1 phase cell cycle arrest in NSCLC in response to LZ-106, an analog of enoxacin, is orchestrated through ROS overproduction in a P53-dependent manner.
    Yang L; Zhou J; Meng F; Fu C; Zou X; Liu J; Zhang C; Tan R; Li Z; Guo Q; Wei L
    Carcinogenesis; 2019 Mar; 40(1):131-144. PubMed ID: 30239617
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The anti-non-small cell lung cancer effect of Diosbulbin B: Targeting YY1 induced cell cycle arrest and apoptosis.
    Zhao JQ; Zhou QQ; Sun Y; Yu T; Jiang Y; Li HJ
    Phytomedicine; 2024 Jul; 130():155734. PubMed ID: 38761775
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Study of the antitumor mechanisms of apiole derivatives (AP-02) from Petroselinum crispum through induction of G0/G1 phase cell cycle arrest in human COLO 205 cancer cells.
    Wu KH; Lee WJ; Cheng TC; Chang HW; Chen LC; Chen CC; Lien HM; Lin TN; Ho YS
    BMC Complement Altern Med; 2019 Jul; 19(1):188. PubMed ID: 31351461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.